Zhidi Lin

Dr. Zhidi Lin


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2022 in Osteoarthritis and Cartilage
Verified
Journal Article
Closed access
ZLZhidi Lin
Zhidi Lin
HWHongli Wang
Hongli Wang
JSJ. Song
J. Song
GXG. Xu
G. Xu
FLF. Lu
F. Lu
FZFei Zou
Fei Zou


18 February 2026 in Journal of Orthopaedic Translation
Verified
Journal Article
Open access
HXHaocheng Xu
Haocheng Xu
LLLinli Li
Linli Li
FZFan Zhang
Fan Zhang
MSMinghao Shao
Minghao Shao
CLChenyan Li
Chenyan Li
FLFeizhou Lyu
Feizhou Lyu
Magnesium-based implants facilitate bone regeneration via degradation. However, the epigenetic mechanisms, particularly N6-methyladenosine (m6A) modification regulated by Mg2+, remain incompletely understood. This study investigated the role of Mg2+ in osteogenic differentiation through the METTL3-RhoA axis and evaluated its potential in intervertebral fusion. The optimal Mg2+ concentration was identified using MC3T3-E1 cells. Methylated RNA immunoprecipitation sequencing (MeRIP-seq) and MeRIP-PCR were employed to identify m6A target genes. Functional assays (knockdown, overexpression, and rescue) validated the METTL3-YTHDF1-RhoA pathway. A rat tail intervertebral fusion model with magnesium implants was used to assess in vivo effects. Treatment with 4 mM Mg2+ significantly enhanced osteogenic activity and increased METTL3 levels. Mechanistically, METTL3 promoted m6A methylation of RhoA mRNA, which was subsequently bound by YTHDF1, enhancing translation and activating the RhoA/ROCK pathway. In vivo, magnesium implants accelerated fusion and improved trabecular bone quality; however, these effects were inhibited by METTL3 or RhoA inhibitors. Mg2+ enhances osteogenic differentiation through the METTL3-YTHDF1-RhoA/ROCK pathway. This study provides an epigenetic framework for optimizing magnesium-based orthopedic implants and suggests that targeting the m6A-RhoA axis could improve spinal fusion outcomes.